ERα degrader-2

ERα degrader-2 is a selective estrogen receptor degrader ( SERD ) with potent binding affinity with ERα ( IC 50 =17.1 nM), good degradation efficacy ( EC 50 =0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability, can be used for HER + breast cancer research In Vitro ERα degrader-2 (0.01-40 nM) decreases ERα expression and not fully degrades ERα in MCF-7 cells even at a higher biochemical concentration in MCF7 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ERα degrader-2 (oral administration; 2-6 mg/kg; QD; 21 days) leads to the significant tumor growth inhibition and decreases tumor volume in mice . ERα degrader-2 (oral gavage; 2 mg/kg; single dose) possesses better pharmacokinetic properties than AZD9496, the plasma exposure (AUC) is 16073.7 h*ng/mL, and the half-life period is 12.1 h, the oral availability is 80.5% . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MCF-7 human breast cancer xenograft model in nude mice Dosage: 2 mg/kg; 6 mg/kg Administration: Oral administration; 2-6 mg/kg; QD; 21 days Result: Exhibited in vivo efficacy in breast cancer xenograft model. Form:Solid IC50& Target:ERα 4.6 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet